Percutaneous renal cryoablation: Prospective experience treating 120 consecutive tumors

American Journal of Roentgenology

Volumn 201, Issue 6, 2013, Pages 1353-1361

  Buy, Xavier ^a   Lang, Herve ^a   Garnon, Julien ^a   Sauleau, Erik ^a   Roy, Catherine ^a   Gangi, Afshin ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Cryoablation; CT intervention; MRI intervention; Percutaneous ablation; Renal cancer; Thermal protection

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CARBODISSECTION; CLINICAL EFFECTIVENESS; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HYDRODISSECTION; KIDNEY FUNCTION; KIDNEY TUMOR; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SAFETY; PERCUTANEOUS RENAL CRYOABLATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEAT PROCEDURE; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TUMOR CLASSIFICATION; TUMOR RECURRENCE; TUMOR VOLUME; UROLOGICAL PROCEDURE;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CRYOSURGERY; FEMALE; HUMANS; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RADIOGRAPHY, INTERVENTIONAL; REOPERATION; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84888309751     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.11084     Document Type: Article

References (29)

1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011; 32:605-644.
2. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5, 628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005; 128:452-462.
3. Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: A systematic review. J Thorac Oncol 2010; 5:260-274.
4. Azzoli CG, Temin S, Aliff T, et al. 2011 focused update of 2009 American Society of Clinical Oncology clinical praCTice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011; 29:3825-3831.
5. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-smallcell lung cancer. J Clin Oncol 2009; 27:591-598.
6. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induCTion therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13:247-255.
7. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 2006; 52:155-163.
8. Gridelli C, Maione P, Rossi A, et al. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 2009; 14:137-147.
9. Grossi F. Management of non-small cell lung in cancer patients with stable disease. Drugs 2012; 72(suppl 1):20-27.
10. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-smallcell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-1440.
11. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.; SATURN Investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11:521-529.
12. Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): A multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012; 13:466-475.
13. Simon CJ, Dupuy DE, DiPetrillo TA, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology 2007; 243:268-275.
14. Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: A prospeCTive, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 2008; 9:621-628.
15. Zhu JC, Yan TD, Morris DL. A systematic review of radiofrequency ablation for lung tumors. Ann Surg Oncol 2008; 15:1765-1774.
16. Dupuy DE. Image-guided thermal ablation of lung malignancies. Radiology 2011; 260:633-655.
17. Li X, Wang J, Li W, et al. Percutaneous CT-guided radiofrequency ablation for unreseCTable hepatocellular carcinoma pulmonary metastases. Int J Hyperthermia 2012; 28:721-728.
18. Lee H, Jin GY, Han YM, et al. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. Cardiovasc Intervent Radiol 2012; 35:343-350.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
20. Pan C, Wu P, Yu J, et al. CT-guided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma. Int J Hyperthermia 2011; 27:549-554.
21. Zhao M, Wang JP, Pan CC, et al. CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unreseCTable hepatocellular carcinoma with long overall survival improvement. Eur J Radiol 2012; 81:2717-2725.
22. Fernando HC, De Hoyos A, Landreneau RJ, et al. Radiofrequency ablation for the treatment of nonsmall cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg 2005; 129:639-644.
23. Pennathur A, Abbas G, Qureshi I, et al. Radiofrequency ablation for the treatment of pulmonary metastases. Ann Thorac Surg 2009; 87:1030-1036; discussion, 1036-1039.
24. Zhang X, Zang J, Xu J, et al. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: A systematic review and meta-analysis. Chest 2011; 140:117-126.
25. Alexander BM, Othus M, Caglar HB, Allen AM. Tumor volume is a prognostic faCTor in non-smallcell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2011; 79:1381-1387.
26. Elias D, Baton O, Sideris L, et al. HepateCTomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unreseCTable multiple coloreCTal liver metastases. J Surg Oncol 2005; 90:36-42.
27. Carrafiello G, Fontana F, Cotta E, et al. Ultrasound- guided thermal radiofrequency ablation (RFA) as an adjunCT to systemic chemotherapy for breast cancer liver metastases. Radiol Med (Torino) 2011; 116:1059-1066.
28. Jin Y, Cai YC, Cao Y, et al. Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes. J Surg Oncol 2012; 106:322-326.
29. Kashima M, Yamakado K, Takaki H, et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: A single center's experiences. AJR 2011; 197:W576-W580.